PAX6 and gastric cancer: The present study revealed the mechanisms of CDK4/6i resistance in GC associated with overexpressed PAX6, a transcriptional factor that can epigenetically inactivate the Hippo signaling pathway, and, therefore, activate cyclin D1 to facilitate CDK4/6i resistance.